Tuesday, June 11, 2019

Daily Update - Tuesday June 11th, 2019

Regulatory -

FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma
FDA
- FDA grants accelerated approval of Polivy to Genentech.  One more approval is always a good day for ADCs in general

Manuscripts -

A Physical Organic Approach to Tuning Reagents for Selective and Stable Methionine Bioconjugation
ChemRxiv
- Cysteine conjugation is now well established for ADCs but can methionines be used to accomplish site-specific conjugation as well.  Look out THIOmab

Boronic acids as building blocks for the construction of therapeutically useful bioconjugates
Royal Society of Chemistry
- A nice review article about using boronic acids to find new bioconjugate targets

Considerations for the Design of Antibody-Based Therapeutics
Journal of Pharmaceutical Sciences
- Its easy to forget that every ADC is based on the mAb.  This is a nice review about the challenges and intricacies of mAb engineering

Clinical Results -

Positive results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Biospectrum Asia
- Phase II clincal results showing that HER2 is not limited to breast cancer.  IND to be filed later this year


-----------------------------
Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me. Justin@ADCDaily.com

No comments:

Post a Comment